Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

ZacksResearch Dec. 24 at 6:09 PM

Biotech momentum is BACK — and these names are already up big 👀🚀 $MLYS, $LYEL, $NKTR and $INSM are all up more than 50% in 2025, powered by clinical wins, FDA approvals, and M&A deals that are reviving confidence across the drug and biotech space heading into 2026. See why these high-flyers may still have room to grow 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-teaser-26257&ADID=SYND_STOCKTWITS_TWEET_2_2808693_TEASER_26257

0 · Reply

BillionerOfKing Dec. 24 at 5:11 PM

$NKTR Current Stock Price: $43.79 Contracts to trade: $45 NKTR Jan 16 2026 Call Entry: $1.20 Exit: $1.96 ROI: 64% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

1Investor9 Dec. 24 at 7:23 AM

Tracked him down. $ABVX is safe. $NKTR will be back in q1. Come collect ur bo

0 · Reply

AdamURAtoFookingNeptune Dec. 24 at 3:16 AM

Sold incy from mid 60s today and averaged up on Nektar. Now just own these 3 in order: $EXEL $UTHR $NKTR

0 · Reply

AdamURAtoFookingNeptune Dec. 24 at 3:08 AM

$NKTR I don’t think this is rolling over but it may chop and grind lower to bore people then a vertical move. Add more over next couple months you’ll have time

0 · Reply

breakoutstock Dec. 23 at 8:54 PM

$NKTR whoa

1 · Reply

george4it Dec. 23 at 1:34 PM

$NKTR As end of year tax selling may continue for a few more days, I will continue to take advantage of the sale prices and add to my trading position. Cheers and happy holidays.

0 · Reply

calbucs Dec. 23 at 3:09 AM

$NKTR here is a spineless one ! Blocked

1 · Reply

calbucs Dec. 23 at 3:08 AM

$NKTR Boy the paid per post hoes are out in full force . Blocking the Trash !

0 · Reply

breakoutstock Dec. 22 at 9:19 PM

$NKTR chicken 🐔 are leaving. Good.

0 · Reply

Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg

Dec 16, 2025, 1:29 PM EST - 8 days ago

Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript

Dec 16, 2025, 11:30 AM EST - 8 days ago

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Dec 15, 2025, 6:00 PM EST - 9 days ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Dec 5, 2025, 6:00 PM EST - 19 days ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2025, 10:59 AM EST - 6 weeks ago

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nov 12, 2025, 12:39 AM EST - 6 weeks ago

Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout

Nov 8, 2025, 5:45 PM EST - 6 weeks ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 7, 2025, 4:26 PM EST - 6 weeks ago

Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:15 PM EST - 6 weeks ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 7 weeks ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 2 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 2 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 2 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 2:31 PM EDT - 3 months ago

Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Sep 18, 2025, 8:45 AM EDT - 3 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 9, 2025, 7:00 AM EDT - 3 months ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 4, 2025, 2:52 PM EDT - 3 months ago

What's Going On With Nektar Therapeutics Stock On Thursday?

Sep 3, 2025, 7:00 PM EDT - 4 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 8, 2025, 7:48 PM EDT - 4 months ago

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:15 PM EDT - 4 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 5 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 5 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 6 months ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 6 months ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 30, 2025, 4:02 PM EDT - 6 months ago

Nektar Therapeutics Announces Proposed Public Offering

Jun 27, 2025, 8:45 AM EDT - 6 months ago

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Jun 25, 2025, 1:42 PM EDT - 6 months ago

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Jun 24, 2025, 1:20 PM EDT - 6 months ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 7:35 AM EDT - 6 months ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 6 months ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 23, 2025, 4:30 PM EDT - 6 months ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Jun 11, 2025, 3:13 PM EDT - 7 months ago

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 7 months ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 8 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 8 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 8 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 8 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 9 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 10 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 10 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 10 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 10 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 10 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 10 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 11 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 1 year ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nov 18, 2024, 3:30 PM EST - 1 year ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nov 14, 2024, 9:11 AM EST - 1 year ago

Multiple Catalysts Ahead For Nektar Therapeutics

ZacksResearch Dec. 24 at 6:09 PM

0 · Reply

BillionerOfKing Dec. 24 at 5:11 PM

0 · Reply

1Investor9 Dec. 24 at 7:23 AM

Tracked him down. $ABVX is safe. $NKTR will be back in q1. Come collect ur bo

0 · Reply

AdamURAtoFookingNeptune Dec. 24 at 3:16 AM

Sold incy from mid 60s today and averaged up on Nektar. Now just own these 3 in order: $EXEL $UTHR $NKTR

0 · Reply

AdamURAtoFookingNeptune Dec. 24 at 3:08 AM

$NKTR I don’t think this is rolling over but it may chop and grind lower to bore people then a vertical move. Add more over next couple months you’ll have time

0 · Reply

breakoutstock Dec. 23 at 8:54 PM

$NKTR whoa

1 · Reply

george4it Dec. 23 at 1:34 PM

$NKTR As end of year tax selling may continue for a few more days, I will continue to take advantage of the sale prices and add to my trading position. Cheers and happy holidays.

0 · Reply

calbucs Dec. 23 at 3:09 AM

$NKTR here is a spineless one ! Blocked

1 · Reply

calbucs Dec. 23 at 3:08 AM

$NKTR Boy the paid per post hoes are out in full force . Blocking the Trash !

0 · Reply

breakoutstock Dec. 22 at 9:19 PM

$NKTR chicken 🐔 are leaving. Good.

0 · Reply

george4it Dec. 22 at 8:54 PM

$NKTR When LLY starts talking to them about a BO, you’ll see it in the share price.

0 · Reply

ShortNKTR Dec. 22 at 8:24 PM

$NKTR $NKTR. No where near a bottom. So many red candles last week.

1 · Reply

ShortNKTR Dec. 22 at 8:22 PM

$NKTR Expect a PR soon saying someone died or FDA already shut it down.

1 · Reply

mreitnour Dec. 22 at 8:20 PM

$NKTR

0 · Reply

ShortNKTR Dec. 22 at 8:17 PM

$NKTR> does 40s hold this week or do we see 39s??? So exciting.

1 · Reply

Mirandiiie Dec. 22 at 8:08 PM

$NKTR Rezpeg study measured how much hair grows back overall on average. While JAK studies measured what % of patients improved their SALT score by at least 20%. That makes Rezpeg look understated in the headlines, when it actually isn’t.

2 · Reply

ShortNKTR Dec. 22 at 7:48 PM

$NKTR $NKTR There is no way to remove the stink of FAILURE. Now AD data cannot be trusted if positive and if they thought it would be positive. They would not be diluting via ATM for 100 million more. This is pure deseperation. They need cash to keep their paychecks cuming. This what failure looks like.

1 · Reply

ShortNKTR Dec. 22 at 7:35 PM

$NKTR. Anyone that says AA data was good is a moron. The data showed that placebo was almost as good. Why are they diluting so much right now if AD is going to be good? They know it will fail like all of the others. If you have a profit, bank it. If you need a move. SHORT all you can here. It is never going higher. Chart is so bad

1 · Reply

ShortNKTR Dec. 22 at 7:32 PM

$NKTR. Todays shareprice is next years 52 week high. Non stop dilution and REZPEG is getting exposed like NKTR 214 and NKTR 181. This is going back to 20 where it belongs.

0 · Reply

Lets_Go_Brndn Dec. 22 at 7:19 PM

$NKTR Is Adam May in this or not?

1 · Reply

Stonky_Mcprofitface Dec. 22 at 6:15 PM

$NKTR This company ALWAYS disappoints

2 · Reply

nesanmano Dec. 22 at 2:45 PM

$NKTR guys, what is the problem with this

2 · Reply

Market Cap	904.41M
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	300,200
Avg Vol	875,412
Day's Range	N/A - N/A
Shares Out	20.34M
Stochastic %K	9%
Beta	1.27
Analysts	Strong Sell
Price Target	$114.43